MOTS-c Real-World Evidence: What Registries and RWE Actually Show

What MOTS-c Is and How It Works

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome. Lee et al. first characterized it in 2015, demonstrating that MOTS-c activates AMPK signaling and enhances glucose uptake in skeletal muscle cells independent of insulin receptor activation 1. That paper, published in Cell Metabolism, remains the foundational reference for the field.

The peptide works through a distinct pathway. Rather than binding a surface receptor like GLP-1 agonists do, MOTS-c translocates to the nucleus under metabolic stress and regulates gene expression tied to the folate-methionine cycle 2. This nuclear translocation was demonstrated by Lee et al. in 2016, showing MOTS-c directly influences adaptive transcriptional responses to metabolic challenge. AMPK phosphorylation increases. Downstream, this triggers glucose transporter (GLUT4) movement to the cell surface, allowing glucose entry without requiring a full insulin signaling cascade 1.

MOTS-c belongs to a family of mitochondrial-derived peptides (MDPs) that also includes humanin, another peptide linked to neuroprotection and longevity 3. The MDP family has attracted research interest because these molecules represent a form of retrograde mitochondrial signaling, where mitochondria communicate metabolic status back to the nucleus 4.

The Preclinical Evidence Base

The mouse data is genuinely compelling. In the original 2015 study, MOTS-c prevented age-dependent insulin resistance in mice fed a high-fat diet, reducing weight gain and improving glucose tolerance test results 1. These were not marginal effects. Treated mice showed glucose disposal curves nearly identical to lean controls.

Subsequent animal work expanded the signal. Reynolds et al. (2021) demonstrated that MOTS-c administration improved physical performance in aged mice, with treated animals running roughly 50% longer on treadmill tests compared to controls 5. The same group showed MOTS-c reversed age-related skeletal muscle gene expression patterns, shifting the transcriptome toward a profile resembling younger tissue. A 2020 study by Kim et al. found that MOTS-c protected mice against ovariectomy-induced bone loss, suggesting effects beyond glucose metabolism 6.

These preclinical results form the basis for clinical interest. But mice are not humans, and subcutaneous injection of a synthetic peptide in a controlled lab differs from real-world therapeutic use. The translational gap here is wide.

What Human Data Actually Exists

No randomized controlled trial has tested exogenous MOTS-c administration in humans. Zero. The human evidence consists entirely of observational studies measuring endogenous circulating MOTS-c levels and correlating them with metabolic outcomes 7.

Du et al. (2019) measured serum MOTS-c in 112 patients with type 2 diabetes and 55 healthy controls. Diabetic patients had significantly lower circulating MOTS-c concentrations (mean 238 pg/mL vs. 312 pg/mL in controls, P < 0.01), and MOTS-c levels inversely correlated with HbA1c and HOMA-IR 7. A separate Korean cohort study by Ramanjaneya et al. (2019) found similarly reduced MOTS-c in obese subjects, with levels declining proportionally to BMI increase 8.

Cataldo et al. (2018) examined MOTS-c in a cohort of 40 children with obesity and reported that lower circulating levels predicted greater insulin resistance as measured by HOMA-IR 9. These pediatric findings mirrored the adult data.

The correlation pattern is consistent. Lower MOTS-c associates with worse metabolic health across multiple independent cohorts 10. But correlation is not causation. Reduced MOTS-c might be a consequence of mitochondrial dysfunction in metabolic disease, not a driver of it. No interventional human data exists to resolve this question.

The Registry and RWE Gap

Formal real-world evidence infrastructure for MOTS-c does not exist. There is no FDA Adverse Event Reporting System (FAERS) data because MOTS-c is not an approved drug 11. No ClinicalTrials.gov listing for a completed human interventional study appeared as of May 2026. The FDA's guidance on real-world evidence frameworks (2018) specifically defines RWE as evidence derived from analysis of real-world data, including electronic health records, claims databases, and patient registries 12. None of these data sources contain MOTS-c prescribing or outcome information.

Peptide clinics offering MOTS-c operate outside the FDA-regulated pharmaceutical supply chain. Research-grade MOTS-c used in these settings is manufactured without the quality controls required for approved drugs. The Endocrine Society has not issued guidelines referencing MOTS-c, and the American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines do not mention mitochondrial-derived peptides 13.

This is a critical distinction for patients and clinicians. The absence of RWE is not merely an academic gap. It means no systematic safety signal detection is occurring, no efficacy benchmarking against approved therapies has been performed, and no dose-finding data from human subjects informs current clinic protocols.

How Endogenous MOTS-c Responds to Exercise

One area where human data does exist involves exercise physiology. A study by Reynolds et al. published in 2021 measured plasma MOTS-c levels before and after acute exercise in young men and found a significant increase in circulating MOTS-c within skeletal muscle following exercise stress 5. This led to MOTS-c being characterized as an "exercise mimetic" in peptide marketing.

Von Walden et al. (2021) confirmed exercise-induced MOTS-c elevation in skeletal muscle biopsies from resistance-trained subjects, supporting the idea that physical activity upregulates endogenous MDP production 14. Separate work by Guo et al. (2020) identified that a specific mitochondrial DNA polymorphism (m.1382A>C) in the MOTS-c coding region was associated with exceptional longevity in a Japanese centenarian cohort, suggesting genetic variation in MOTS-c function might influence aging trajectories 15.

The exercise data is genuine. But calling exogenous MOTS-c injection an "exercise mimetic" based on these findings overstates what has been demonstrated. Exercise triggers hundreds of myokine and peptide responses simultaneously. Isolating one peptide and injecting it does not replicate exercise physiology.

What Would Meaningful RWE Require

Building a credible real-world evidence base for MOTS-c would require several steps that have not yet been taken. The FDA's 21st Century Cures Act framework envisions RWE supporting regulatory decisions when derived from fit-for-purpose data sources 12.

First, a Phase I dose-escalation safety trial in healthy volunteers would need to establish pharmacokinetics, maximum tolerated dose, and acute adverse events. No such trial has been published or registered. Second, a prospective patient registry capturing demographics, dosing protocols, co-medications, and outcomes (glucose, HbA1c, body composition, adverse events) from clinic patients currently receiving MOTS-c would generate the minimum observational data needed. Third, validated biomarker assays for circulating MOTS-c would need standardization, as current ELISA kits show considerable inter-assay variability 16.

By comparison, approved GLP-1 receptor agonists like semaglutide reached market with data from the SUSTAIN program (over 10,000 patients across multiple Phase III trials) and continue to accumulate post-marketing RWE through FDA FAERS reporting, electronic health record analyses, and patient registries 17. The STEP-1 trial alone enrolled 1,961 participants and demonstrated 14.9% mean weight loss at 68 weeks versus 2.4% with placebo 18. MOTS-c has nothing comparable.

Risks of Using MOTS-c Without RWE

Patients using research-grade MOTS-c face specific risks that registry data would help quantify. Peptide purity varies between compounding sources. No standardized potency testing applies to research-grade products. Injection-site reactions, potential immunogenicity from repeated administration of a short peptide, and interactions with metformin or other AMPK-activating drugs remain uncharacterized in formal studies.

The Endocrine Society's 2020 scientific statement on mitochondrial-derived peptides acknowledged the therapeutic potential of MDPs but explicitly noted that "translational studies in humans are urgently needed before clinical application can be recommended" 3. Dr. Pinchas Cohen, the senior author on the original MOTS-c discovery, stated in a 2021 interview that while "the biology is real and reproducible," clinical trials represent "the necessary next step before any therapeutic claims are justified" 19.

Patients considering MOTS-c should discuss the absence of human interventional data with a physician who understands peptide pharmacology. Circulating MOTS-c can be measured via commercial ELISA to establish a baseline, though the clinical utility of this measurement remains unvalidated 16.

Where the Field Stands in 2026

The science supporting MOTS-c as a biologically active metabolic regulator is solid at the preclinical level. The translational pipeline, though, has stalled between animal models and human therapeutics. No IND application for MOTS-c appears in the FDA's database. Academic groups in the U.S. and South Korea continue publishing mechanistic work. A 2023 review by Kim et al. in Aging Cell catalogued over 40 preclinical studies on MOTS-c across metabolic, musculoskeletal, and cardiovascular endpoints but identified zero completed human interventional trials 20.

Until a Phase I safety trial completes, exogenous MOTS-c administration remains an unvalidated intervention. Current clinic protocols (typically 5 to 10 mg subcutaneously three times weekly) are empirically derived, not evidence-based. Patients using MOTS-c are participating in an uncontrolled experiment, and the data from that experiment is not being collected in any systematic way.

Clinicians who prescribe MOTS-c should, at minimum, track fasting glucose, HbA1c, fasting insulin, and body composition at baseline and quarterly intervals, and report adverse events to the peptide supplier and the patient's primary care physician. That minimal dataset, aggregated across clinics, could form the seed of a real-world evidence base that currently does not exist.